used radiation therapy to induce tumor secretion of IL-8 (CXCL8), and found that CD70-CAR-engineered T cells expressing either of the IL-8 receptors CXCR1 or CXCR2, showed enhanced migration and persistence, leading to complete tumor regression and immunologic memory in models of aggressive tumors, including glioblastoma, ovarian, and pancreatic cancers (176). This evidence concerns the gene CXCR2 and neoplasm.